Literature DB >> 16816072

Comparative outcomes of bladder cancer.

Marylou Cárdenas-Turanzas1, Catherine Cooksley, Curtis A Pettaway, Anita Sabichi, H Barton Grossman, Linda Elting.   

Abstract

OBJECTIVE: To compare the survival of women and men with transitional cell bladder cancer.
METHODS: We used the Surveillance Epidemiology and End Results database to identify patients aged 35 years or older diagnosed with bladder cancer between 1991 and 2001 actively followed up. We excluded cases diagnosed by autopsy or death certificates and those of unknown race. We used Cox proportional hazard regression to analyze survival in patients with advanced disease.
RESULTS: Of the 31,009 patients meeting eligibility criteria, 26.7% were women. Median age at diagnosis for women and men was 72 and 70 years, respectively. Regional disease was diagnosed in 20.3% of white women and 35.5% of African-American women, compared with only 17.6% of white men and 25.9% of African-American men (P < .001). Increased age, African-American race, and being female significantly increased the hazard of death (hazard ratio [HR] 1.037, 95% confidence interval [CI] 1,034-1.041; HR 1.402, 95% CI 1.187-1.656; and HR 1.842, 95% CI 1.158-2.931).
CONCLUSION: Women with bladder cancer, particularly African-Americans, have shorter survival. This is partially explained by higher risk of diagnosis with poorly differentiated tumors, advanced stage, and advanced age. Women should be targeted for timely diagnosis. LEVEL OF EVIDENCE: II-2.

Entities:  

Mesh:

Year:  2006        PMID: 16816072     DOI: 10.1097/01.AOG.0000223885.25192.91

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  Is there a gender effect in bladder cancer? A population-based study of practice and outcomes.

Authors:  Francis Michael Patafio; D Robert Siemens; Xuejiao Wei; Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.

Authors:  Anita L Sabichi; J Jack Lee; H Barton Grossman; Suyu Liu; Ellen Richmond; Bogdan A Czerniak; Jorge De la Cerda; Craig Eagle; Jaye L Viner; J Lynn Palmer; Seth P Lerner
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

3.  Gender, race, and variation in the evaluation of microscopic hematuria among Medicare beneficiaries.

Authors:  Jeffrey C Bassett; JoAnn Alvarez; Tatsuki Koyama; Matthew Resnick; Chaochen You; Shenghua Ni; David F Penson; Daniel A Barocas
Journal:  J Gen Intern Med       Date:  2014-12-02       Impact factor: 5.128

4.  Genome-Wide DNA Methylation in Prediagnostic Blood and Bladder Cancer Risk in the Women's Health Initiative.

Authors:  Kristina M Jordahl; Timothy W Randolph; Xiaoling Song; Cassandra L Sather; Lesley F Tinker; Amanda I Phipps; Karl T Kelsey; Emily White; Parveen Bhatti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-14       Impact factor: 4.254

5.  Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study.

Authors:  Marylou Cárdenas-Turanzas; Catherine Cooksley; Ashish M Kamat; Curtis A Pettaway; Linda S Elting
Journal:  Int Urol Nephrol       Date:  2008-03-04       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.